Multiple Sclerosis: Revised Scoping Document for Relapsing-Remitting MS
A Final Scoping Document to inform development of ICER’s report on therapies for treatment of multiple sclerosis. A draft version of this document was open to a three-week public comment period, during which time ICER received and considered a number of comments from patients, clinical experts, drug manufacturers, and other stakeholders.
While this document outlines ICER’s plan of research for therapies to treat relapsing-remitting multiple sclerosis, ICER has also issued an addendum to the draft scope that includes the use of ocrelizumab and rituximab for patients with primary-progressive multiple sclerosis (PPMS). The addendum will remain open to public comment until Friday, August 12, at 5:00 pm PT. More information is available here.View All Materials on this Topic or Go Back to View More Materials